JP2016507533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507533A5 JP2016507533A5 JP2015556344A JP2015556344A JP2016507533A5 JP 2016507533 A5 JP2016507533 A5 JP 2016507533A5 JP 2015556344 A JP2015556344 A JP 2015556344A JP 2015556344 A JP2015556344 A JP 2015556344A JP 2016507533 A5 JP2016507533 A5 JP 2016507533A5
- Authority
- JP
- Japan
- Prior art keywords
- staphylococcus
- subspecies
- bacillus
- streptococcus
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000191940 Staphylococcus Species 0.000 claims 14
- 239000004721 Polyphenylene oxide Substances 0.000 claims 6
- 239000002555 ionophore Substances 0.000 claims 6
- 230000000236 ionophoric effect Effects 0.000 claims 6
- 229920000570 polyether Polymers 0.000 claims 6
- 230000001580 bacterial effect Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 241000191967 Staphylococcus aureus Species 0.000 claims 4
- 208000004396 mastitis Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- -1 rasaloside Chemical compound 0.000 claims 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims 3
- 241000194033 Enterococcus Species 0.000 claims 3
- 229930191564 Monensin Natural products 0.000 claims 3
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims 3
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 claims 3
- 239000004189 Salinomycin Substances 0.000 claims 3
- 241001147736 Staphylococcus capitis Species 0.000 claims 3
- 241000194049 Streptococcus equinus Species 0.000 claims 3
- WQGJEAMPBSZCIF-WHSSCRKSSA-N azanium;2-[(2r,3s,4s,5r,6s)-6-[(1r)-1-[(2r,5r,7s,8r,9s)-2-[(2s,5r)-5-[(2r,3s,5r)-3-[(2r,4s,5s,6s)-4,5-dimethoxy-6-methyloxan-2-yl]oxy-5-[(2s,3s,5r,6s)-6-hydroxy-3,5,6-trimethyloxan-2-yl]oxolan-2-yl]-5-methyloxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxasp Chemical compound [NH4+].O1[C@@H](C)[C@H](OC)[C@@H](OC)C[C@H]1O[C@@H]1[C@H]([C@]2(C)O[C@@H](CC2)[C@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](O)C3)[C@@H](C)[C@H]3[C@@H]([C@@H](OC)[C@H](C)[C@@](O)(CC([O-])=O)O3)OC)CC2)O[C@@H]([C@@H]2[C@H](C[C@@H](C)[C@@](C)(O)O2)C)C1 WQGJEAMPBSZCIF-WHSSCRKSSA-N 0.000 claims 3
- 229960005358 monensin Drugs 0.000 claims 3
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims 3
- 229960001548 salinomycin Drugs 0.000 claims 3
- 235000019378 salinomycin Nutrition 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 241000186042 Actinomyces bovis Species 0.000 claims 2
- 241000194108 Bacillus licheniformis Species 0.000 claims 2
- 241000194103 Bacillus pumilus Species 0.000 claims 2
- 241000186427 Cutibacterium acnes Species 0.000 claims 2
- 241001464975 Cutibacterium granulosum Species 0.000 claims 2
- 241000186394 Eubacterium Species 0.000 claims 2
- 229930182504 Lasalocid Natural products 0.000 claims 2
- VHKXXVVRRDYCIK-CWCPJSEDSA-N Narasin Chemical compound C[C@H]1C[C@H](C)[C@H]([C@@H](CC)C(O)=O)O[C@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-CWCPJSEDSA-N 0.000 claims 2
- VHKXXVVRRDYCIK-UHFFFAOYSA-N Narasin Natural products CC1CC(C)C(C(CC)C(O)=O)OC1C(C)C(O)C(C)C(=O)C(CC)C1C(C)CC(C)C2(C=CC(O)C3(OC(C)(CC3)C3OC(C)C(O)(CC)CC3)O2)O1 VHKXXVVRRDYCIK-UHFFFAOYSA-N 0.000 claims 2
- 241000191992 Peptostreptococcus Species 0.000 claims 2
- 241000201854 Staphylococcus chromogenes Species 0.000 claims 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 2
- 241000191984 Staphylococcus haemolyticus Species 0.000 claims 2
- 241000192087 Staphylococcus hominis Species 0.000 claims 2
- 241000794282 Staphylococcus pseudintermedius Species 0.000 claims 2
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims 2
- 241000191978 Staphylococcus simulans Species 0.000 claims 2
- 241000192086 Staphylococcus warneri Species 0.000 claims 2
- 241000191973 Staphylococcus xylosus Species 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 claims 2
- 229960000320 lasalocid Drugs 0.000 claims 2
- 229960001851 narasin Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229940055019 propionibacterium acne Drugs 0.000 claims 2
- 229940037649 staphylococcus haemolyticus Drugs 0.000 claims 2
- 229940037648 staphylococcus simulans Drugs 0.000 claims 2
- 229940115921 streptococcus equinus Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 241000193755 Bacillus cereus Species 0.000 claims 1
- 244000063299 Bacillus subtilis Species 0.000 claims 1
- 235000014469 Bacillus subtilis Nutrition 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241000193403 Clostridium Species 0.000 claims 1
- 241000193468 Clostridium perfringens Species 0.000 claims 1
- 241001478240 Coccus Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- 241000186779 Listeria monocytogenes Species 0.000 claims 1
- 241000206591 Peptococcus Species 0.000 claims 1
- 241001464878 Peptoniphilus indolicus Species 0.000 claims 1
- 241000205160 Pyrococcus Species 0.000 claims 1
- 241001147695 Staphylococcus caprae Species 0.000 claims 1
- 241000194048 Streptococcus equi Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- 241000194054 Streptococcus uberis Species 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940065181 bacillus anthracis Drugs 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 210000005075 mammary gland Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940115922 streptococcus uberis Drugs 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013900411 | 2013-02-08 | ||
| AU2013900411A AU2013900411A0 (en) | 2013-02-08 | Methods Of Treating Microbial Infections, Including Mastitis | |
| PCT/AU2014/000102 WO2014121343A1 (en) | 2013-02-08 | 2014-02-10 | Methods of treating microbial infections, including mastitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016507533A JP2016507533A (ja) | 2016-03-10 |
| JP2016507533A5 true JP2016507533A5 (enExample) | 2017-03-16 |
| JP6779619B2 JP6779619B2 (ja) | 2020-11-04 |
Family
ID=51299091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556344A Active JP6779619B2 (ja) | 2013-02-08 | 2014-02-10 | 乳房炎をはじめとする微生物感染を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11491105B2 (enExample) |
| EP (1) | EP2953624B1 (enExample) |
| JP (1) | JP6779619B2 (enExample) |
| KR (1) | KR20150115837A (enExample) |
| CN (2) | CN113559264A (enExample) |
| AU (1) | AU2014214548B2 (enExample) |
| CA (1) | CA2900373C (enExample) |
| MX (1) | MX375254B (enExample) |
| NZ (1) | NZ710757A (enExample) |
| RU (1) | RU2662300C2 (enExample) |
| WO (1) | WO2014121343A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104586855A (zh) * | 2014-12-29 | 2015-05-06 | 天津市中升挑战生物科技有限公司 | 一种复方利福昔明子宫注入剂及其制备方法与应用 |
| CN104774223A (zh) * | 2015-03-26 | 2015-07-15 | 宁夏泰瑞制药股份有限公司 | 一种利用泰乐菌素碱生产泰地罗新的方法 |
| CN107216353B (zh) * | 2016-03-21 | 2020-05-19 | 山东诚创医药技术开发有限公司 | 一种头孢洛林酯咪唑盐的精制方法 |
| CN107536864B (zh) * | 2016-06-23 | 2020-12-25 | 西安乐民反刍动物研究所 | 用于反刍动物常见外科疾病的预防治疗喷剂及制备方法 |
| WO2018019031A1 (en) * | 2016-07-27 | 2018-02-01 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | A pharmaceutical composition comprising an ionophore and a beta-lactam antibiotic and use thereof |
| CN106727294A (zh) * | 2016-12-23 | 2017-05-31 | 常州润诺生物科技有限公司 | 一种硫酸依替米星的口服制剂及其制备方法与应用 |
| CN108671000B (zh) * | 2018-07-04 | 2021-05-28 | 佛山市南海东方澳龙制药有限公司 | 一种复方药剂及其用途 |
| WO2020194298A1 (en) * | 2019-03-25 | 2020-10-01 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Method of treating bovine mastitis |
| CN110368394B (zh) * | 2019-06-25 | 2022-10-11 | 华中农业大学 | 一种阿维拉霉素在猪产气荚膜梭菌抑制药物中的应用 |
| CN110376366B (zh) * | 2019-07-19 | 2020-10-02 | 吉林大学 | 一种烟酸通过gpr109a受体应用于治疗奶牛乳腺炎的实验方法 |
| CN111514142B (zh) * | 2020-05-29 | 2021-04-06 | 江苏亚虹医药科技股份有限公司 | 含硝羟喹啉前药的药物组合物及其制备方法和应用 |
| US20240058366A1 (en) | 2020-12-24 | 2024-02-22 | Intervet Inc. | Methods of treating mastitis with an orthosomycin antimicrobial compound |
| CN112870166B (zh) * | 2021-01-20 | 2022-04-08 | 中山大学 | 一种核丛青霉素固体分散体、制备方法及应用 |
| CN113040094B (zh) * | 2021-03-18 | 2022-06-21 | 中国农业大学 | 一种牛支原体性小鼠乳腺炎模型的构建方法及其应用 |
| RU2762088C1 (ru) * | 2021-05-05 | 2021-12-15 | Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии" (ФГБНУ "ВНИВИПФиТ") | Способ лечения мастита у коров |
| KR102818865B1 (ko) * | 2022-07-26 | 2025-06-13 | 주식회사 인트론바이오테크놀로지 | 젖소유방염 치료용 항균단백질 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2171966B1 (enExample) * | 1972-02-17 | 1975-03-14 | Pierrefitte Auby Sa | |
| AU4633893A (en) * | 1992-06-17 | 1994-01-04 | University Of Massachusetts Medical Center | Liposomal formulations for administering to cancer patients |
| AU720243B2 (en) * | 1996-06-20 | 2000-05-25 | Novartis Ag | Method for the prevention and treatment of mastitis |
| EP1086947A1 (en) * | 1999-09-01 | 2001-03-28 | Pfizer Products Inc. | Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| AU2004222523A1 (en) * | 2003-03-20 | 2004-09-30 | Pharmacia Corporation | Dispersible formulation of an anti-inflammatory agent |
| AR054639A1 (es) * | 2004-02-02 | 2007-07-11 | Bimeda Res & Dev Ltd | Un metodo y dispositivo |
| EP2138171A1 (en) * | 2008-06-18 | 2009-12-30 | Istituto Superiore Di Sanita' | Veterinarian compositions containing terpinen-4-ol for the treatment and prevention of mastitis |
| BRPI1002601E2 (pt) * | 2010-06-01 | 2020-06-30 | Embrapa Pesquisa Agropecuaria | composição nanoestruturada de uso veterinário para administração de fármacos |
| MX2013013182A (es) * | 2011-05-12 | 2013-12-09 | Intervet Int Bv | Tratamiento de la mastitis. |
| CN104379151A (zh) * | 2012-06-29 | 2015-02-25 | 拜尔动物保健有限责任公司 | 药物组合物和乳腺炎的治疗 |
-
2014
- 2014-02-10 WO PCT/AU2014/000102 patent/WO2014121343A1/en not_active Ceased
- 2014-02-10 CA CA2900373A patent/CA2900373C/en active Active
- 2014-02-10 JP JP2015556344A patent/JP6779619B2/ja active Active
- 2014-02-10 KR KR1020157023384A patent/KR20150115837A/ko not_active Ceased
- 2014-02-10 US US14/766,233 patent/US11491105B2/en active Active
- 2014-02-10 CN CN202110478170.0A patent/CN113559264A/zh active Pending
- 2014-02-10 CN CN201480019196.7A patent/CN105492005A/zh active Pending
- 2014-02-10 MX MX2015010191A patent/MX375254B/es active IP Right Grant
- 2014-02-10 AU AU2014214548A patent/AU2014214548B2/en active Active
- 2014-02-10 NZ NZ710757A patent/NZ710757A/en unknown
- 2014-02-10 EP EP14749117.9A patent/EP2953624B1/en active Active
- 2014-02-10 RU RU2015132211A patent/RU2662300C2/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016507533A5 (enExample) | ||
| JP2016507532A5 (enExample) | ||
| Gao et al. | Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA) | |
| Nigo et al. | What’s new in the treatment of enterococcal endocarditis? | |
| Holmes et al. | What's new in the treatment of serious MRSA infection? | |
| Roberts et al. | Size and composition of synthetic calcium sulfate beads influence dissolution and elution rates in vitro | |
| HK1222297A1 (zh) | 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途 | |
| CO2018001407A2 (es) | Composiciones con potenciadores de permeación para suministro de fármacos | |
| MX359989B (es) | Fármacos antivirales para el tratamiento de la infección por arenavirus. | |
| NZ704011A (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
| NZ713946A (en) | Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections | |
| HRP20151095T1 (hr) | Farmaceutski pripravci koji sadrže rifaksimin, postupci za njihovu proizvodnju i njihova primjena u lijeäśenju vaginalnih infekcija | |
| JP2013508269A5 (enExample) | ||
| UY33003A (es) | Asociaciones farmacéuticas, composiciones farmacéuticas, medicamento y método para el tratamiento de animales | |
| FI3006038T3 (fi) | Oritavansiinin yksittäisannokset bakteeri-infektion hoitoon tai ehkäisyyn | |
| AU2019301069A8 (en) | Mixing/administration system for vaccines and medicaments | |
| BR112021017878A2 (pt) | Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação | |
| GEP20186857B (en) | Saturated nitrogen and n-acylated heterocycles potentiating the activity of an active antibiotic against mycobacteria | |
| Dryden et al. | Infection prevention in wounds with Surgihoney | |
| MX353876B (es) | Metodo para el tratamiento de una infeccion. | |
| AR064152A1 (es) | Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion. | |
| WO2016004216A3 (en) | Hydrogels for treating and ameliorating infections and methods of making and using them | |
| Cunha et al. | Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy | |
| MY184630A (en) | Tylosin derivatives and method for preparation thereof | |
| Cañamares-Orbis et al. | Is high-dose intravenous fosfomycin safe for the treatment of patients prone to heart failure? |